Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. AAPL
6. TRMD
7. ONON
8. AZN
9. BETR
10. NVDA

Go back to Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 0.79 +0.06 (8.22%)
Previous Close $0.73    52 Week High $0.94 
Open $0.73    52 Week Low $0.47 
Day High $0.81    P/E N/A 
Day Low $0.71    EPS $-0.11 
Volume 161,250